CLINICAL_TRIALS
trial_result
· 2014-11-03
Clinical Trial Update: Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies [Phase 3]
Summary
Phase 3 trial evaluating febuxostat to prevent tumor lysis syndrome in hematologic malignancies has completed and results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Menarini Group | Conditions: Tumor Lysis Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2014-11-03